Summary
GlobalData, the industry analysis specialist's new report, "Women's Infertility-Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global women's infertility market. The report identifies the key trends shaping and driving the global women's Infertility market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global women's infertility sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The report analyzes the opportunities and challenges for the global women's infertility disease market. It includes 
-Annualized global women's infertility disease market revenues data from 2001 to 2009, forecast for seven years to 2016.
-Geographic markets covered in this report are the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include GnRH antagonists, AMP-activated protein kinase (AMPK) agonists, luteinising hormone stimulators and Beta 2 receptor agonists.
-Analysis of the current and future competitors in the global women's infertility market. The key market players covered are Merck Serono SA, Ferring Pharmaceuticals, Dong-A Pharmaceutical Co., Ltd. and PregLem SA.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
-The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future women's infertility market.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global women's infertility  market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global women's infertility market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global women's infertility market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Women's Infertility: Market Characterization 4
2.1 Overview 4
2.2 Women's Infertility Market Size 4
2.3 Women's Infertility Market Forecast and CAGR 5
2.4 Drivers and Barriers for Women's Infertility Market 6
2.4.1 Drivers for Women's Infertility Market 6
2.4.2 Barriers for Women's Infertility Market 6
2.5 Opportunity and Unmet Need 6
2.6 Key Takeaway 7
3 Women's Infertility Market: Competitive Assessment 8
3.1 Overview 8
3.2 Strategic Competitor Assessment 8
3.3 Major Therapies in the Women's Infertility Market 9
3.3.1 Clomid (clomiphene citrate) 9
3.3.2 Ovidrel (choriogonadotropin alfa) 9
3.3.3 GONAL-f (follitropin alfa) 10
3.3.4 Cetrotide (cetrorelix acetate) 11
3.4 Major Marketed Products Comparison in the Women's Infertility Market 13
3.5 Key Takeaway 13
4 Women's Infertility Market: Pipeline Assessment 14
4.1 Overview 14
4.2 Strategic Pipeline Assessment 14
4.2.1 Technology Trends Analytic Framework 14
4.3 Women's Infertility Therapeutics-Promising Drugs Under Clinical Development 15
4.4 Molecule Profile for Promising Drugs under Clinical Development 15
4.4.1 ELONVA (corifollitropin alfa injection) 15
4.5 Women's Infertility Therapeutics Market-Clinical Pipeline by Therapeutic Class 16
4.6 Women's Infertility Disease Pipeline-Pipeline by Clinical Phases of Development 17
4.6.1 Women's Infertility Therapeutics-Regulatory Filed Clinical Pipeline 17
4.6.2 Women's Infertility Therapeutics-Phase III Clinical Pipeline 17
4.6.3 Women's Infertility Therapeutics-Phase II Clinical Pipeline 18
4.6.4 Women's Infertility Therapeutics-Phase I Clinical Pipeline 18
4.6.5 Women's Infertility Therapeutics-Preclinical Pipeline 18
4.6.6 Women's Infertility Therapeutics-Discovery Pipeline 18
4.7 Key Takeaway 18
5 Global Women's Infertility Market: Implications for Future Market Competition 19
6 Global Women's Infertility Market: Future Players in the Women's Infertility Market 20
6.1 Introduction 20
6.2 Merck Serono S.A. 20
6.2.1 Company Overview 20
6.3 Dong-A Pharmaceutical Co., Ltd. 22
6.3.1 Company Overview 22
6.4 Ferring Pharmaceuticals 23
6.4.1 Company Overview 23
6.5 PregLem SA 24
6.5.1 Company Overview 24
7 Global Women's Infertility Market: Appendix 25
7.1 Definitions 25
7.2 Acronyms 25
7.3 Research Methodology 26
7.3.1 Coverage 26
7.3.2 Secondary Research 27
7.3.3 Forecasting 27
7.3.4 Primary Research 30
7.3.5 Expert Panels 30
7.4 Contact Us 30
7.5 Disclaimer 30
7.6 Sources 31

List of Tables
1.1 List of Tables
Table 1:  Global Women's Infertility Market, Historic Revenue ($m), 2001-2009 5
Table 2:  Global Women's Infertility Market, Revenue Forecasts ($ m), 2009-2016 5
Table 3:  Major Marketed Products Comparison in the Women's Infertility Market, 2010 13
Table 4:  Women's Infertility Therapeutics-Most Promising Drugs Under Clinical Development, 2010 15
Table 5:  Women's Infertility Therapeutics-Regulatory Filed, 2010 17
Table 6:  Women's Infertility Therapeutics-Phase III Clinical Pipeline, 2010 17
Table 7:  Women's Infertility Therapeutics-Phase II Clinical Pipeline, 2010 18
Table 8:  Women's Infertility Therapeutics-Phase I Clinical Pipeline, 2010 18
Table 9:  Women's Infertility Therapeutics-Preclinical Pipeline, 2010 18
Table 10:  Women's Infertility Therapeutics-Preclinical Pipeline, 2010 18
Table 11:  Merck Serono S.A.-Women's Healthcare Pipeline Products, 2010 21
Table 12:  Merck Serono S.A.-Women's Infertility Pipeline Products, 2010 21
Table 13:  Dong-A Pharmaceutical Co., Ltd.-Women's Health Pipeline Products, 2010 23
Table 14:  Dong-A Pharmaceutical Co., Ltd.-Women's Infertility Pipeline Products, 2010 23
Table 15:  Ferring Pharmaceuticals-Women's Health Pipeline Products, 2010 23
Table 16:  Ferring Pharmaceuticals-Women's Infertility Pipeline Products, 2010 23
Table 17:  PregLem SA-Women's Health Pipeline Products, 2010 24
Table 18:  PregLem SA-Women's Infertility Pipeline Products, 2010 24

List of Figures
1.2 List of Figures
Figure 1:  Global Women's Infertility Market Forecasts ($m), 2001-2016 5
Figure 2:  Women's Infertility Market-Opportunity and Unmet Need, 2010 7
Figure 3:  Women's Infertility Market-Strategic Competitor Assessment, 2010 8
Figure 4:  Technology Trends Analytic Framework of the  Women's Infertility Pipeline, 2010 14
Figure 5:  Technology Trends Analytic Framework of the Women's Infertility Pipeline-Description, 2010 15
Figure 6:  Women's Infertility Market-Clinical Pipeline by Mechanism Of Action, 2010 16
Figure 7:  Women's Infertility Pipeline by Phase of Clinical Development, 2010 17
Figure 8:  Women's Infertility Therapeutics Market-Strategic Competitor Assessment, 2010 19
Figure 9:  Women's Infertility Therapeutics Market-Clinical Pipeline by Company, 2010 20
Figure 10:  GlobalData Methodology, 2010 26
Figure 11:  GlobalData Market Forecasting Model, 2010 29